查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1933365

全球膀胱癌疫苗市場：市場規模、佔有率、成長率、產業分析、依類型、應用和地區劃分的考量因素以及未來預測（2026-2034）

Bladder Cancer Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 167 Pages | 商品交期: 請詢問到貨日

價格

膀胱癌疫苗市場成長因素

預計2025年全球膀胱癌疫苗市場規模將達到3,504.6億美元，2026年將成長至4174.3億美元，2034年將達到24,233.7億美元，預測期內複合年增長率（CAGR）為24.59%。歐洲在2025年將佔市場主導地位，市場佔有率達36.31%，這主要歸功於膀胱癌的高發病率、完善的醫療保健基礎設施以及治療性疫苗的日益普及。膀胱癌是全球最常見的癌症之一，卡介苗 (BCG) 疫苗可有效治療，主要用於非肌肉層浸潤性膀胱癌 (NMIBC)。膀胱癌發病率的上升以及生活方式相關的風險因素，例如長期接觸致癌物和吸煙，正在推動全球對膀胱癌疫苗的需求。

默克、鹽野義製藥株式會社和 ImmunityBio, Inc. 等領先企業正在大力投資研發，並擴大其全球業務，以鞏固其市場地位。持續的創新和新的在研產品正在推動成長，確保未來十年市場前景穩健。

市場動態

成長因素：膀胱癌發生率的上升是推動成長的關鍵因素。根據世界癌症研究基金會 (WCRF) 2022 年的報告，預計全球新增膀胱癌病例將達到 614,289 例，凸顯了治療介入的緊迫性。醫療機構擴大採用卡介苗 (BCG) 疫苗治療早期非肌肉層浸潤性膀胱癌 (NMIBC)，這正在推動市場需求。

市場限制因素：目前，缺乏替代疫苗療法是限制市場發展的主要因素。卡介苗是目前唯一獲準用於治療膀胱癌的疫苗，但正如膀胱癌倡導網絡 (Bladder Cancer Advocacy Network) 在 2020 年報告的那樣，供應短缺和效率低下可能會限制患者獲得疫苗的機會，並抑制市場成長。

機會：專注於新型候選疫苗的研發 (R&D) 蘊藏著巨大的商機。下一代疫苗旨在提高安全性、易用性和有效性。例如，鹽野義製藥株式會社於2021年完成了其S-588410癌症勝肽疫苗的II期臨床試驗，展現了治療研發領域的創新。

挑戰：臨床試驗的高失敗率阻礙了成長。腫瘤異質性和免疫反應的變異性使有效膀胱癌免疫療法的研發變得複雜。延遲和供應鏈挑戰，例如Ferring Pharmaceuticals在2024年遇到的情況，影響了及時供應和分銷。

市場趨勢

一個重要的趨勢是疫苗和免疫療法的整合。聯合療法正被越來越多地用於促進免疫活化並降低對卡介苗（BCG）無反應患者的復發率。 2024年4月，美國食品藥物管理局 (FDA) 批准了諾加潘地喹α/invaxcept-PMLN 與卡介苗 (BCG) 聯合用於治療對 BCG 治療無效的非肌肉層浸潤性膀胱癌 (NMIBC) 患者。這項療法正在重塑治療方案，並推動市場擴張。

市場區隔分析

依產品劃分：BCG 疫苗佔市場主導地位，是目前唯一獲得商業核准的治療性疫苗。策略聯盟，例如 ImmunityBio 與印度血清研究所於 2024 年 5 月達成的協議，將支持下一代重組 BCG 疫苗的研發，用於 ANKTIVA 等聯合療法。

依給藥途徑劃分：膀胱內給藥途徑佔領先地位，該途徑透過標靶遞送降低全身毒性和腫瘤復發率。 RUTIVAC-1 研究（EAU25，2025）的臨床證據表明，膀胱內注射卡介苗可增強免疫反應。

依分銷管道劃分：由於需要經認證的醫療監督，醫院是膀胱內給藥的主要管道。 ImmunityBio 與 Urology Partners 達成的 2025 年合作協議等合作項目，有助於解決供應短缺問題，並加強醫院分銷。

區域展望

歐洲：預計 2025 年歐洲市場規模將達到 1,272.6 億美元，在高發病率和研究計畫的推動下，歐洲市場將引領成長。 2025 年，歐洲將通報超過 22.4 萬例膀胱癌新病例，其中光是歐盟就將有 16.5 萬例。

北美：先進的醫療基礎設施預計將支持卡介苗的普及，推動市場以 31.3% 的複合年增長率成長。預計到 2034 年，診斷技術的發展以及持續的研發將推動市場規模達到 9,300 萬美元。

亞太地區：中國和印度膀胱癌發病率的上升以及醫療保健的不斷擴展，使該地區成為第三大市場。

拉丁美洲、中東和非洲：由於膀胱癌發病率的上升以及對有效疫苗需求的增長，預計該地區將保持溫和增長。

目錄

第一章：引言

第二章：摘要整理

第三章：市場動態

  • 市場驅動因素
  • 市場限制因素
  • 市場機遇
  • 市場趨勢

第四章：關鍵考慮因素

  • 主要國家和地區膀胱癌盛行率（2025 年）
  • 主要國家及地區監理概況
  • 主要公司研發管線分析
  • 關鍵趨勢：併購、業務合作、新產品發布、核准等

第五章：全球膀胱癌癌症疫苗市場分析：洞察與預測（2021-2034）

  • 市場分析、洞察與預測：依產品分類
    • 卡介苗 (BCG)
    • 其他
  • 市場分析、洞察與預測：依給藥途徑分類
    • 膀胱內給藥
    • 其他
  • 市場分析、洞察與預測：依通路分類
    • 醫院
    • 政府及機構供應
    • 其他
  • 市場分析、洞察與預測：依地區分類
    • 北美
    • 歐洲
    • 亞太地區
    • 拉丁美洲
    • 中東和非洲

第六章 北美膀胱癌疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 美國
    • 加拿大

第七章：歐洲膀胱癌疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 斯堪的納維亞
    • 歐洲其他地區

第八章：亞太地區膀胱癌疫苗市場分析：洞察與預測（2021-2034）

  • 依國家/地區
    • 中國
    • 日本
    • 印度
    • 東南亞
    • 澳大利亞
    • 亞太其他地區

第九章：拉丁美洲膀胱癌疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地區

第十章：中東與非洲膀胱癌疫苗市場分析：洞察與預測（2021-2034）

  • 依國家劃分
    • 海灣合作委員會（GCC）國家
    • 南非
    • 中東其他地區非洲

第11章 競爭分析

  • 全球市場佔有率分析(2025年)
  • 企業簡介
  • Merck &Co., Inc.,
  • Shionogi &Co., Ltd.
  • ImmunityBio, Inc.
  • Altor BioScience, LLC
  • Hamlet BioPharma.
  • Asieris Pharmaceuticals.
  • Pfizer Inc.
Product Code: FBI113882

Growth Factors of bladder cancer vaccines Market

The global bladder cancer vaccines market was valued at USD 350.46 billion in 2025 and is projected to grow to USD 417.43 billion in 2026, eventually reaching USD 2,423.37 billion by 2034, exhibiting a CAGR of 24.59% during the forecast period. Europe dominated the market in 2025 with a 36.31% share, driven by the high prevalence of bladder cancer, established healthcare infrastructure, and increased adoption of therapeutic vaccines. Bladder cancer, one of the most prevalent cancers worldwide, can be treated effectively with Bacillus Calmette-Guerin (BCG) vaccines, primarily for non-muscle invasive bladder cancers (NMIBCs). Rising incidence rates and lifestyle-related risk factors, such as prolonged exposure to carcinogens and smoking, are fueling the demand for bladder cancer vaccines globally.

Leading players, including Merck & Co., Inc., Shionogi & Co., Ltd., and ImmunityBio, Inc., are investing heavily in research and development (R&D) and expanding their global presence to strengthen their market positions. Continuous innovations and new pipeline candidates are driving growth, ensuring a robust market outlook for the coming decade.

Market Dynamics

Drivers: The increasing prevalence of bladder cancer is the primary growth driver. According to the World Cancer Research Fund 2022, there were 614,289 new bladder cancer cases globally, reflecting the urgent need for therapeutic interventions. Healthcare providers are increasingly adopting BCG vaccines for early-stage NMIBCs, boosting market demand.

Restraints: The market is currently constrained by the lack of alternative vaccine treatments. BCG remains the only approved vaccine for bladder cancer, and shortages or inefficiencies, such as those reported by the Bladder Cancer Advocacy Network in 2020, may limit patient access and restrict growth.

Opportunities: Emphasis on R&D for new vaccine candidates presents lucrative opportunities. Next-generation vaccines aim to improve safety, ease of administration, and efficacy. For example, Shionogi & Co., Ltd. completed a Phase II study of the S-588410 cancer peptide vaccine in 2021, showcasing innovation in therapeutic development.

Challenges: High clinical trial failures hamper growth. Tumor heterogeneity and variable immune responses make developing effective bladder cancer immunotherapies complex. Delays and supply chain challenges, such as those experienced by Ferring Pharmaceuticals in 2024, impact timely availability and adoption.

Market Trends

A key trend is the integration of vaccines with immunotherapies. Patients unresponsive to BCG are increasingly receiving combination treatments to enhance immune activation and reduce relapse rates. In April 2024, the FDA approved Nogapendekin alfa inbakicept-pmln with BCG for BCG-unresponsive NMIBC patients. This approach is reshaping treatment protocols and supporting market expansion.

Segmentation Analysis

By Product: The BCG segment dominates the market, being the only commercially approved therapeutic vaccine. Strategic partnerships, such as ImmunityBio's collaboration with the Serum Institute of India in May 2024, support next-generation recombinant BCG development for combination therapies like ANKTIVA.

By Route of Administration: The intravesical segment leads due to its targeted delivery, reducing systemic toxicity and lowering tumor recurrence. Clinical evidence from the RUTIVAC-1 Trial (EAU25, 2025) demonstrates enhanced immune response when BCG is administered intravesically.

By Distribution Channel: Hospitals dominate due to certified medical supervision required for intravesical administration. Collaborations, such as ImmunityBio's partnership with U.S. Urology Partners in 2025, address shortages and reinforce hospital-based distribution.

Regional Outlook

Europe: Led the market in 2025 with USD 127.26 billion, driven by high incidence and research initiatives. Over 224,000 new bladder cancer cases were reported in Europe in 2025, with 165,000 in the EU alone.

North America: Projected to grow at 31.3% CAGR, with advanced healthcare infrastructure supporting adoption. The region is expected to reach USD 93.0 million by 2034, driven by diagnostics and ongoing R&D.

Asia Pacific: Positioned as the third-largest market due to rising prevalence and healthcare expansion in China and India.

Latin America & Middle East & Africa: Moderate growth is anticipated due to increasing bladder cancer incidence and demand for effective vaccines.

Competitive Landscape

The market is concentrated, dominated by Merck & Co., Shionogi & Co., ImmunityBio, Altor BioScience, and others. These companies leverage R&D, collaborations, and global distribution to strengthen their positions. Notable developments include:

  • August 2025: Hamlet BioPharma completed Phase II alpha1h study in NMIBC patients.
  • January 2025: Pfizer's Phase III CREST trial evaluated sasanlimab with BCG for high-risk NMIBC.
  • July 2025: ImmunityBio received UK MHRA approval for ANKTIVA combined with BCG.

Conclusion

The global bladder cancer vaccines market is set to grow from USD 350.46 billion in 2025 to USD 417.43 billion in 2026, reaching USD 2,423.37 billion by 2034 at a CAGR of 24.59%. Europe remains the dominant region, supported by rising prevalence and extensive research initiatives. Growth is fueled by the increasing burden of bladder cancer, strategic partnerships, combination therapies, and the development of next-generation vaccines. Despite challenges such as clinical trial failures and reliance on BCG, ongoing R&D and immunotherapy integrations are expected to drive substantial advancements, making the market highly promising for key players and new entrants alike.

Segmentation By Product

  • Bacillus Calmette-Guerin (BCG)
  • Others

By Route of Administration

  • Intravesical
  • Others

By Distribution Channel

  • Hospitals
  • Government & Organization Supply
  • Others

By Geography

  • North America (By Product, Route of Administration, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Product, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Germany
    • U.K.
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Product, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • Japan
    • India
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Product, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Product, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology
  • 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence of Bladder Cancers, by Key Countries/ Region, 2025
  • 4.2. Overview of Regulatory Scenario by Key Countries/Regions
  • 4.3. Pipeline Analysis, Key Players
  • 4.4. Key Industry Developments - Mergers, Acquisitions, Partnerships, Launches, Approvals, etc.

5. Global Bladder Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Product
    • 5.1.1. Bacillus Calmette-Guerin (BCG)
    • 5.1.2. Others
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Intravesical
    • 5.2.2. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospitals
    • 5.3.2. Government & Organization Supply
    • 5.3.3. Others
  • 5.4. Market Analysis, Insights and Forecast - Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Bladder Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Product
    • 6.1.1. Bacillus Calmette-Guerin (BCG)
    • 6.1.2. Others
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Intravesical
    • 6.2.2. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospitals
    • 6.3.2. Government & Organization Supply
    • 6.3.3. Others
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
    • 6.4.2. Canada

7. Europe Bladder Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Product
    • 7.1.1. Bacillus Calmette-Guerin (BCG)
    • 7.1.2. Others
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Intravesical
    • 7.2.2. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospitals
    • 7.3.2. Government & Organization Supply
    • 7.3.3. Others
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 7.4.1. U.K.
    • 7.4.2. Germany
    • 7.4.3. France
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Scandinavia
    • 7.4.7. Rest of Europe

8. Asia Pacific Bladder Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Product
    • 8.1.1. Bacillus Calmette-Guerin (BCG)
    • 8.1.2. Others
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Intravesical
    • 8.2.2. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospitals
    • 8.3.2. Government & Organization Supply
    • 8.3.3. Others
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 8.4.1. China
    • 8.4.2. Japan
    • 8.4.3. India
    • 8.4.4. Southeast Asia
    • 8.4.5. Australia
    • 8.4.6. Rest of Asia Pacific

9. Latin America Bladder Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Product
    • 9.1.1. Bacillus Calmette-Guerin (BCG)
    • 9.1.2. Others
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Intravesical
    • 9.2.2. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospitals
    • 9.3.2. Government & Organization Supply
    • 9.3.3. Others
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 9.4.1. Brazil
    • 9.4.2. Mexico
    • 9.4.3. Rest of Latin America

10. Middle East & Africa Bladder Cancer Vaccines Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Product
    • 10.1.1. Bacillus Calmette-Guerin (BCG)
    • 10.1.2. Others
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Intravesical
    • 10.2.2. Others
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospitals
    • 10.3.2. Government & Organization Supply
    • 10.3.3. Others
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
    • 10.4.1. GCC
    • 10.4.2. South Africa
    • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles (Overview, Product, SWOT analysis, Recent developments, strategies, financials (based on availability))
    • 11.2.1. Merck & Co., Inc.,
    • 11.2.2. Shionogi & Co., Ltd.
    • 11.2.3. ImmunityBio, Inc.
    • 11.2.4. Altor BioScience, LLC
    • 11.2.5. Hamlet BioPharma.
    • 11.2.6. Asieris Pharmaceuticals.
    • 11.2.7. Pfizer Inc.

List of Tables

  • Table 1: Global Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Product, 2021-2034
  • Table 2: Global Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Route of Administration, 2021-2034
  • Table 3: Global Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Region, 2021-2034
  • Table 5: North America Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Product, 2021-2034
  • Table 6: North America Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Route of Administration, 2021-2034
  • Table 7: North America Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Country, 2021-2034
  • Table 9: Europe Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Product, 2021-2034
  • Table 10: Europe Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Route of Administration, 2021-2034
  • Table 11: Europe Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Distribution Channel, 2021-2034
  • Table 12: Europe Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Country/ Sub-region, 2021-2034
  • Table 13: Asia Pacific Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Product, 2021-2034
  • Table 14: Asia Pacific Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Route of Administration, 2021-2034
  • Table 15: Asia Pacific Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Distribution Channel, 2021-2034
  • Table 16: Asia Pacific Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Country/ Sub-region, 2021-2034
  • Table 17: Latin America Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Product, 2021-2034
  • Table 18: Latin America Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Route of Administration, 2021-2034
  • Table 19: Latin America Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Distribution Channel, 2021-2034
  • Table 20: Latin America Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Country/ Sub-region, 2021-2034
  • Table 21: Middle East & Africa Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Product, 2021-2034
  • Table 22: Middle East & Africa Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Route of Administration, 2021-2034
  • Table 23: Middle East & Africa Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Distribution Channel, 2021-2034
  • Table 24: Middle East & Africa Bladder Cancer Vaccines Market Revenue (USD million) Forecast, by Country/ Sub-region, 2021-2034

List of Figures

  • Figure 1: Global Bladder Cancer Vaccines Market Revenue Breakdown (USD million, %) by Region, 2025 & 2034
  • Figure 2: Global Bladder Cancer Vaccines Market Value Share (%), by Product, 2025 & 2034
  • Figure 3: Global Bladder Cancer Vaccines Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 4: Global Bladder Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 5: Global Bladder Cancer Vaccines Market Value Share (%), by Region, 2025 & 2034
  • Figure 6: North America Bladder Cancer Vaccines Market Value (USD million), by Product, 2025 & 2034
  • Figure 7: North America Bladder Cancer Vaccines Market Value Share (%), by Product, 2025
  • Figure 8: North America Bladder Cancer Vaccines Market Value (USD million), by Route of Administration, 2025 & 2034
  • Figure 9: North America Bladder Cancer Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 10: North America Bladder Cancer Vaccines Market Value (USD million), by Distribution Channel, 2025 & 2034
  • Figure 11: North America Bladder Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 12: North America Bladder Cancer Vaccines Market Value (USD million), by Country, 2025 & 2034
  • Figure 13: North America Bladder Cancer Vaccines Market Value Share (%), by Country, 2025
  • Figure 14: Europe Bladder Cancer Vaccines Market Value (USD million), by Product, 2025 & 2034
  • Figure 15: Europe Bladder Cancer Vaccines Market Value Share (%), by Product, 2025
  • Figure 16: Europe Bladder Cancer Vaccines Market Value (USD million), by Route of Administration, 2025 & 2034
  • Figure 17: Europe Bladder Cancer Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 18: Europe Bladder Cancer Vaccines Market Value (USD million), by Distribution Channel, 2025 & 2034
  • Figure 19: Europe Bladder Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Europe Bladder Cancer Vaccines Market Value (USD million), by Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Bladder Cancer Vaccines Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Bladder Cancer Vaccines Market Value (USD million), by Product, 2025 & 2034
  • Figure 23: Asia Pacific Bladder Cancer Vaccines Market Value Share (%), by Product, 2025
  • Figure 24: Asia Pacific Bladder Cancer Vaccines Market Value (USD million), by Route of Administration, 2025 & 2034
  • Figure 25: Asia Pacific Bladder Cancer Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 26: Asia Pacific Bladder Cancer Vaccines Market Value (USD million), by Distribution Channel, 2025 & 2034
  • Figure 27: Asia Pacific Bladder Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 28: Asia Pacific Bladder Cancer Vaccines Market Value (USD million), by Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Bladder Cancer Vaccines Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 30: Latin America Bladder Cancer Vaccines Market Value (USD million), by Product, 2025 & 2034
  • Figure 31: Latin America Bladder Cancer Vaccines Market Value Share (%), by Product, 2025
  • Figure 32: Latin America Bladder Cancer Vaccines Market Value (USD million), by Route of Administration, 2025 & 2034
  • Figure 33: Latin America Bladder Cancer Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 34: Latin America Bladder Cancer Vaccines Market Value (USD million), by Distribution Channel, 2025 & 2034
  • Figure 35: Latin America Bladder Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 36: Latin America Bladder Cancer Vaccines Market Value (USD million), by Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Bladder Cancer Vaccines Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Bladder Cancer Vaccines Market Value (USD million), by Product, 2025 & 2034
  • Figure 39: Middle East & Africa Bladder Cancer Vaccines Market Value Share (%), by Product, 2025
  • Figure 40: Middle East & Africa Bladder Cancer Vaccines Market Value (USD million), by Route of Administration, 2025 & 2034
  • Figure 41: Middle East & Africa Bladder Cancer Vaccines Market Value Share (%), by Route of Administration, 2025
  • Figure 42: Middle East & Africa Bladder Cancer Vaccines Market Value (USD million), by Distribution Channel, 2025 & 2034
  • Figure 43: Middle East & Africa Bladder Cancer Vaccines Market Value Share (%), by Distribution Channel, 2025
  • Figure 44: Middle East & Africa Bladder Cancer Vaccines Market Value (USD million), by Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Bladder Cancer Vaccines Market Value Share (%), by Country/ Sub-region, 2025
  • Figure 46: Global Bladder Cancer Vaccines Market Share (%), by Company, 2025